东方证券股份有限公司 关于苏州富士莱医药股份有限公司 部分首次公开发行前已发行股份上市流通的核查意见 东方证券股份有限公司（以下简称"东方证券"或"保荐机构"）作为苏州 富士莱医药股份有限公司（以下简称"富士莱"或"公司"）首次公开发行股票 并在创业板上市的保荐机构，根据《证券发行上市保荐业务管理办法》《深圳证 券交易所创业板股票上市规则》《深圳证券交易所上市公司自律监管指引第 2 号——创业板上市公司规范运作》《深圳证券交易所上市公司自律监管指引第 13 号——保荐业务》等法律法规的有关规定，对富士莱本次部分首次公开发行前已 发行股份上市流通的事项进行了审慎核查，具体情况如下： 一、公司首次公开发行股票的情况 （一）首次公开发行股票情况 经中国证券监督管理委员会《关于同意苏州富士莱医药股份有限公司首次公 开发行股票注册的批复》（证监许可〔2022〕251号）同意注册，公司首次公开 向社会公众发行人民币普通股（A股）股票2,292万股，每股面值人民币1.00元， 每股发行价格为48.30元。公司总股本由6,875.00万股变更为9,167.00万股，其中 有限售条件的股份数量为69,934,117股，占公司总 ...

Group 1 - The stock price of Fujilai (301258.SZ) decreased by 4.35%, closing at 34.29 yuan [1] - Fujilai was listed on the Shenzhen Stock Exchange's ChiNext board on March 29, 2022, with an issuance of 22.92 million shares at a price of 48.30 yuan per share [1] - The stock reached its highest price of 80.39 yuan on its first trading day, but is currently in a state of decline [1] Group 2 - The total amount raised from the initial public offering (IPO) was 1.107 billion yuan, with a net amount of 1.003 billion yuan after deducting issuance costs [1] - The net amount raised exceeded the original plan by 333 million yuan [1] - The IPO expenses totaled 104 million yuan, with underwriting and sponsorship fees amounting to approximately 78.8 million yuan [1] Group 3 - The funds raised are intended for projects including the expansion of production capacity for 720 tons of pharmaceutical intermediates and raw materials, a research and development center, information technology construction, and to supplement working capital [1]

Group 1 - The company Fuji Lai (301258) responded to investor inquiries on September 12, indicating that as of September 10, 2025, the total number of shareholders is 11,450 [1]

Group 1 - The company announced the appointment of Bian Aijin as the secretary of the board, deputy general manager, and chief financial officer [2]

根据《公司法》等法律法规及《公司章程》的规定，全体董事一致同意选举 钱祥云先生担任公司第五届董事会董事长，任期自本次董事会审议通过之日起至 第五届董事会任期届满之日止。 表决结果：7 票同意、0 票反对、0 票弃权。 具体内容详见同日刊登在巨潮资讯网（www.cninfo.com.cn）的《关于董事会 完成换届选举、聘任高级管理人员的公告》（公告编号：2025-050）。 证券代码：301258 证券简称：富士莱 公告编号：2025-049 苏州富士莱医药股份有限公司 第五届董事会第一次会议决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 苏州富士莱医药股份有限公司（以下简称"公司"）第五届董事会第一次会 议于 2025 年 9 月 11 日下午 16 时在公司会议室以现场与通讯表决方式召开，经 全体董事同意豁免本次会议的通知时间要求，会议通知在公司 2025 年第二次临 时股东大会取得表决结果后，以电话、口头等方式发出。全体董事共同推举钱祥 云先生主持本次会议。本次会议应到董事 7 人，实到董事 7 人。公司高级管理人 员列席了本次会议。会议的召集、召 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-050 一、第五届董事会及专门委员会组成情况 | 序号 | 姓名 | 职位 | | --- | --- | --- | | 1 | 钱祥云 | 非独立董事（董事长） | | 2 | 卞爱进 | 非独立董事 | | 3 | 沈莹娴 | 非独立董事 | | 4 | 陆建刚 | 职工代表董事 | | 5 | 陈忠 | 独立董事（会计专业人士） | | 6 | 曹传兴 | 独立董事 | | 7 | 董炳和 | 独立董事 | 1、董事会组成情况 上述人员简历详见附件。公司第五届董事会任期自 2025 年第二次临时股东 大会审议通过之日起三年。公司第五届董事会中兼任公司高级管理人员及由职工 代表担任的董事人数总计未超过公司董事总数的二分之一，独立董事人数不低于 董事会成员总数的三分之一，符合相关法律法规及《公司章程》的规定。独立董 事的任职资格和独立性已经深圳证券交易所审核无异议。 | 专门委员会名称 | 主任委员（召集人） | 全体委员 | | --- | --- | --- | | 审计委员会 | 陈忠 | 陈忠、董炳和、陆建刚 | | 战略委员会 | 钱 ...

上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公司 2025 年第二次临时股东大会的 法律意见书 地址：苏州市姑苏区人民路 3110 号国发大厦南楼 907 电话：0512-67872033 上海兰迪（苏州）律师事务所 法律意见书 上海兰迪（苏州）律师事务所 关于苏州富士莱医药股份有限公司 2025 年第二次临时股东大会的 法律意见书 致：苏州富士莱医药股份有限公司 上海兰迪（苏州）律师事务所（以下简称"本所"）接受苏州富士莱医药股份有 限公司（以下简称"公司"）的委托，就贵公司召开的 2025 年第二次临时股东大会 （以下简称"本次股东大会"）进行见证并就相关事宜出具本法律意见书。 本所律师根据《中华人民共和国公司法》（以下简称"《公司法》"）、《中华 人民共和国证券法》（以下简称"《证券法》"）、《上市公司股东会规则》（以下 简称"《股东会规则》"）、《深圳证券交易所上市公司股东大会网络投票实施细则》 以及《苏州富士莱医药股份有限公司章程》（以下简称"《公司章程》"）等规定， 就本次股东大会的召集和召开程序、召集人资格和出席会议人员资格、会议表决程序 和表决 ...

证券代码：301258 证券简称：富士莱 公告编号：2025-048 苏州富士莱医药股份有限公司 2025 年第二次临时股东大会决议公告 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假记载、误导 性陈述或者重大遗漏。 特别提示： 1.本次股东大会不存在否决议案的情形。 2.本次股东大会不涉及变更以往股东大会已通过的决议。 一、会议召开情况 （一）会议召开的时间 1、现场会议时间：2025 年 9 月 11 日下午 14:30。 （1）通过深圳证券交易所交易系统进行网络投票的时间为： 2025 年 9 月 11 日上午 9:15-9:25，9:30-11:30，下午 13:00-15:00； （2）通过深圳证券交易所互联网投票系统进行网络投票的时间为 2025 年 9 月 11 日 9:15-15:00。 （二）现场会议召开地点：江苏省常熟市新材料产业园海旺路 16 号 （三）股权登记日：2025 年 9 月 5 日（星期五） （四）会议召开方式：现场表决和网络表决相结合的方式。同一表决权只能 选择现场投票或网络投票表决方式中的一种，不能重复投票，同一表决权出现重 复表决的以第一次有效投票决定结 ...

Summary of Key Points Core Viewpoint - As of August 28, 2025, 3,970 companies have released their semi-annual reports, with 2,129 reporting year-on-year profit growth, while 1,841 experienced declines. Revenue growth was reported by 2,304 companies, with 1,666 seeing a decrease. Notably, 1,603 companies had both profit and revenue growth, while 1,140 reported declines in both metrics. A total of 471 companies saw their profit growth double, with Xinte Electric leading at an astonishing 49,775.01% increase [1]. Group 1: Profit and Revenue Performance - 2,129 companies reported a year-on-year increase in net profit, while 1,841 companies reported a decrease [1]. - 2,304 companies experienced a year-on-year increase in operating revenue, with 1,666 companies reporting a decline [1]. - Xinte Electric had the highest profit growth rate at 49,775.01%, with a net profit of 5.33 million and operating revenue of 192.65 million [1]. Group 2: Notable Companies and Their Performance - Fujilai reported a net profit of 43.08 million with a year-on-year increase of 12,430.96% and operating revenue of 223.91 million [1]. - Honghe Technology achieved a net profit of 87.38 million, marking a 10,587.74% increase, with operating revenue of 550.37 million [1]. - Shubida's net profit reached 10.15 million, reflecting a 5,972.30% increase, with operating revenue of 204.96 million [1]. Group 3: Additional Company Insights - The company Shibibai reported a net profit of 29.23 million, with a year-on-year increase of 5,914.22% and operating revenue of 84.93 million [1]. - Taiji Co. reported a net profit of 39.73 million, with a year-on-year increase of 3,789.41% and operating revenue of 178.79 million [1]. - Other notable companies include Guangda Tongchuang with a net profit of 23.22 million and a 2,699.69% increase, and operating revenue of 749.88 million [1].

Summary of Key Points Core Viewpoint - A total of 628 stocks reported their latest shareholder numbers as of August 20, with 326 stocks showing a decline in shareholder numbers compared to the previous period, indicating a trend of decreasing investor interest in certain stocks [1][3]. Group 1: Shareholder Changes - Among the 628 stocks, 34 stocks experienced a decline in shareholder numbers exceeding 10% [3]. - The stock with the largest decline in shareholder numbers was Huakang Clean, which saw a decrease of 27.60% to 10,900 shareholders [3][4]. - Other notable declines included Sheyan Institute with a 24.78% drop and Jiangshun Technology with a 24.66% drop [3][4]. Group 2: Stock Performance - The average increase for concentrated stocks from August 1 to August 10 was 6.34%, slightly underperforming the Shanghai Composite Index, which rose by 6.36% [2]. - Among the stocks with a decline in shareholder numbers, Anpeilong had the highest increase of 51.31% since August 1 [2][3]. - Stocks such as Dongtianwei and Hangzhou High-tech also showed significant gains of 38.18% and 33.92%, respectively [2][3]. Group 3: Industry Insights - The concentrated stocks are primarily found in the machinery, basic chemicals, and pharmaceutical industries, with 45, 34, and 27 stocks respectively [3]. - The performance of concentrated stocks from August 11 onwards averaged an increase of 2.15%, with leading stocks including Boyuan Co., Beifang Rare Earth, and *ST Jinglun [3][4]. Group 4: Financial Performance - Among the concentrated stocks, 179 have reported their semi-annual results, with Fuji Lai showing the highest net profit growth of 12,430.96% [4]. - Companies like Yalian Machinery and Donghua Technology reported net profit growths of 20.57% and 14.64%, respectively [4].